menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Data, Tools, and Insights on Using Antiarrhythmic Drugs in Atrial Fibrillation Management

This satellite symposium examines the latest data and recommendations for antiarrhythmic drugs in managing atrial fibrillation in the post-CABANA era.

Live Meeting
2.00 available credits
Information
April 29, 2022
11:45 AM - 01:45 PM PDT
InterContinental San Francisco
Grand Ballroom A & B - 3rd Floor, 888 Howard Street, San Francisco, California, United States
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    This live satellite symposium describes the variety of antiarrhythmic drugs that are available and presents the rationale for using them to manage atrial fibrillation. This clinician-oriented program focuses on both inpatient and outpatient care. Issues such as which drug class to use, the adverse effects (QT prolongation), drug-drug interactions, organ toxicity, tradeoffs, cost, effect on length of hospital stay, and how and when to use IV antiarrhythmic drugs will be highlighted.

    This program is not part of the 2022 Heart Rhythm Scientific Sessions as planned by the Scientific Sessions Program Committee.
    This event is neither sponsored nor endorsed by the Heart Rhythm Society.

  • Program Schedule*

    11:45 am–12:00 pm

    Registration and Lunch

    12:00 pm–12:05 pm

    Welcome, Introductions, Program Overview
    T. Jared Bunch, MD
    Dhanunjaya “DJ” Lakkireddy, MD
    Program Chairs

    12:05 pm–12:25 pm


    12:25 pm-12:35 pm

    Antiarrhythmic Drugs in the Management of Atrial Fibrillation
    Bradley P. Knight, MD

    Case Presentation Followed by Panel Discussion
    Ben Steinberg, MD
    All Faculty

    12:35 pm–12:55 pm



    12:55 pm-1:05 pm

    Considerations on Using Antiarrhythmics When Providing Inpatient or Outpatient Care
    T. Jared Bunch, MD

    Case Presentation Followed by Panel Discussion
    Ben Steinberg, MD and Faculty

    1:05 pm–1:25 pm

    Is There a Role for Antiarrhythmic Drugs in the Era of Catheter Ablation?
    Dhanunjaya “DJ” Lakkireddy, MD

    1:25 pm–1:35 pm

    Case Presentation with Panel Discussion
    Ben Steinberg, MD
    All Faculty

    1:35 pm–1:45 pm

    Q&A moderated by Co-Chairs
    All Faculty



    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Program Chairs:

    T. Jared Bunch, MD
    Professor of Medicine
    University of Utah School of Medicine
    Salt Lake City, UT

    Dhanunjaya “DJ” Lakkireddy, MD
    Medical Director, Kansas City Heart Rhythm Institute
    HCA Midwest Health
    Overland Park, KS

    Faculty:

    Bradley P. Knight, MD
    Director, Cardiac Electrophysiology at Northwestern Medicine
    Director, Heart Rhythm Center at the Bluhm Cardiovascular Institute
    Chester C. and Deborah M. Cooley Distinguished Professor of Cardiology
    Professor of Medicine (Cardiology) and Medical Education
    Northwestern Feinberg School of Medicine
    Chicago, IL

    Benjamin A. Steinberg, MD, MHS, FACC, FHRS
    Associate Professor of Medicine
    Cardiovascular Medicine Division
    University of Utah
    Salt Lake City, UT

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the clinical consequences of atrial fibrillation (AF) including the impact of AF on hospitalizations and healthcare resources
    • Explain the importance of making sinus rhythm an important achievable goal in specific patient subgroups through the use of antiarrhythmic drug therapies
    • Describe the antiarrhythmic drug classes for use in AF cardioversion
    • Describe clinical algorithms for selecting antiarrhythmic drugs based on patient and drug characteristics
    • Explain how to convert IV formulations of an antiarrhythmic drug used in AF cardioversion into oral therapy once sinus rhythm has been achieved
  • Target Audience

    This activity is designed to meet the educational needs of electrophysiologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 120-minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from AltaThera Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    This live satellite symposium describes the variety of antiarrhythmic drugs that are available and presents the rationale for using them to manage atrial fibrillation. This clinician-oriented program focuses on both inpatient and outpatient care. Issues such as which drug class to use, the adverse effects (QT prolongation), drug-drug interactions, organ toxicity, tradeoffs, cost, effect on length of hospital stay, and how and when to use IV antiarrhythmic drugs will be highlighted.

    This program is not part of the 2022 Heart Rhythm Scientific Sessions as planned by the Scientific Sessions Program Committee.
    This event is neither sponsored nor endorsed by the Heart Rhythm Society.

  • Program Schedule*

    11:45 am–12:00 pm

    Registration and Lunch

    12:00 pm–12:05 pm

    Welcome, Introductions, Program Overview
    T. Jared Bunch, MD
    Dhanunjaya “DJ” Lakkireddy, MD
    Program Chairs

    12:05 pm–12:25 pm


    12:25 pm-12:35 pm

    Antiarrhythmic Drugs in the Management of Atrial Fibrillation
    Bradley P. Knight, MD

    Case Presentation Followed by Panel Discussion
    Ben Steinberg, MD
    All Faculty

    12:35 pm–12:55 pm



    12:55 pm-1:05 pm

    Considerations on Using Antiarrhythmics When Providing Inpatient or Outpatient Care
    T. Jared Bunch, MD

    Case Presentation Followed by Panel Discussion
    Ben Steinberg, MD and Faculty

    1:05 pm–1:25 pm

    Is There a Role for Antiarrhythmic Drugs in the Era of Catheter Ablation?
    Dhanunjaya “DJ” Lakkireddy, MD

    1:25 pm–1:35 pm

    Case Presentation with Panel Discussion
    Ben Steinberg, MD
    All Faculty

    1:35 pm–1:45 pm

    Q&A moderated by Co-Chairs
    All Faculty



    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Program Chairs:

    T. Jared Bunch, MD
    Professor of Medicine
    University of Utah School of Medicine
    Salt Lake City, UT

    Dhanunjaya “DJ” Lakkireddy, MD
    Medical Director, Kansas City Heart Rhythm Institute
    HCA Midwest Health
    Overland Park, KS

    Faculty:

    Bradley P. Knight, MD
    Director, Cardiac Electrophysiology at Northwestern Medicine
    Director, Heart Rhythm Center at the Bluhm Cardiovascular Institute
    Chester C. and Deborah M. Cooley Distinguished Professor of Cardiology
    Professor of Medicine (Cardiology) and Medical Education
    Northwestern Feinberg School of Medicine
    Chicago, IL

    Benjamin A. Steinberg, MD, MHS, FACC, FHRS
    Associate Professor of Medicine
    Cardiovascular Medicine Division
    University of Utah
    Salt Lake City, UT

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the clinical consequences of atrial fibrillation (AF) including the impact of AF on hospitalizations and healthcare resources
    • Explain the importance of making sinus rhythm an important achievable goal in specific patient subgroups through the use of antiarrhythmic drug therapies
    • Describe the antiarrhythmic drug classes for use in AF cardioversion
    • Describe clinical algorithms for selecting antiarrhythmic drugs based on patient and drug characteristics
    • Explain how to convert IV formulations of an antiarrhythmic drug used in AF cardioversion into oral therapy once sinus rhythm has been achieved
  • Target Audience

    This activity is designed to meet the educational needs of electrophysiologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 120-minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from AltaThera Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Schedule22 May 2022
Webpack App